Claims for Patent: 9,758,586

Summary for Patent: 9,758,586

Title:	Chimeric rabbit/human ROR1 antibodies
Abstract:	The invention relates to antibodies having specificity for human ROR1, compositions thereof, and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with aberrant ROR1 expression.
Inventor(s):	Rader; Christoph (Jupiter, FL), Yang; Jiahui (Kunming, CN)
Assignee:	The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC)
Application Number:	13/990,977
Patent Claims:	1. An antibody having specificity for the extracellular domain of human receptor tyrosine kinase-like orphan receptor 1 (ROR1), comprising complementarity-determining regions (CDRs) with the following sequences: (a) SEQ ID NO: 31 as light chain CDR1 (LCDR1), SEQ ID NO: 32 as LCDR2, SEQ ID NO: 33 as LCDR3, SEQ ID NO: 40 as heavy chain CDR1 (HCDR1), SEQ ID NO: 41 as HCDR2, and SEQ ID NO: 42 as HCDR3, (b) SEQ ID NO: 34 as LCDR1, SEQ ID NO: 35 as LCDR2, SEQ ID NO: 36 as LCDR3, SEQ ID NO: 43 as HCDR1, SEQ ID NO: 42 as HCDR2, and SEQ ID NO: 43 as HCDR3, or (c) SEQ ID NO: 37 as LCDR1, SEQ ID NO: 38 as LCDR2, SEQ ID NO: 39 as LCDR3, SEQ ID NO: 46 as HCDR1, SEQ ID NO: 47 as HCDR2, and SEQ ID NO: 48 as HCDR3. 2. The antibody of claim 1, wherein the antibody comprises (a) a light chain variable domain having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable domain having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 2, (b) a light chain variable domain having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 3 and a heavy chain variable domain having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 4, or (c) a light chain variable domain having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 5 and a heavy chain variable domain having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 6. 3. The antibody of claim 2, wherein (a) the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 1 and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 2; (b) the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 3 and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 4; or (c) the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 5 and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 6. 4. The antibody of claim 1, wherein the light chain variable domain consists of the amino acid sequence of SEQ ID NO: 1 and the heavy chain variable domain consists of the amino acid sequence of SEQ ID NO: 2. 5. The antibody of claim 1, wherein the light chain variable domain consists of the amino acid sequence of SEQ ID NO: 3 and the heavy chain variable domain consists of the amino acid sequence of SEQ ID NO: 4. 6. The antibody of claim 1, wherein the light chain variable domain consists of the amino acid sequence of SEQ ID NO: 5 and the heavy chain variable domain consists of the amino acid sequence of SEQ ID NO: 6. 7. The antibody of claim 1, wherein the antibody is conjugated to a synthetic molecule. 8. The antibody of claim 7, wherein the synthetic molecule comprises a transmembrane region and an intracellular T-cell receptor (TCR) signaling domain. 9. The antibody of claim 7, wherein the synthetic molecule is a label, cytotoxic agent, a therapeutic radioisotope, or a liposome. 10. The antibody of claim 9, wherein the cytotoxic agent is a toxin. 11. The antibody of claim 7, wherein the synthetic molecule is another antibody. 12. The antibody of claim 11, wherein the synthetic molecule is rituximab or bevacuzimab. 13. A pharmaceutical composition comprising a therapeutically effective amount of an isolated antibody of claim 1 and a pharmaceutically acceptable carrier. 14. A kit comprising the isolated antibody of claim 1. 15. The kit of claim 14, further comprising one or more immunoassay buffers. 16. The antibody of claim 1, comprising the following CDR sequences: SEQ ID NO: 31 as LCDR1, SEQ ID NO: 32 as LCDR2, SEQ ID NO: 33 as LCDR3, SEQ ID NO: 40 as HCDR1, SEQ ID NO: 41 as HCDR2, and SEQ ID NO: 42 as HCDR3. 17. The antibody of claim 1, wherein the antibody is a humanized antibody. 18. A conjugate comprising the antibody of claim 1 and a cytotoxic agent. 19. The conjugate of claim 18, wherein the cytotoxic agent is a toxin. 20. The conjugate of claim 19, wherein the toxin is a fragment of Pseudomonas exotoxin A (PE). 21. The conjugate of claim 20, wherein the fragment of PE is PE38. 22. The antibody of claim 1, comprising the following CDR sequences: SEQ ID NO: 34 as LCDR1, SEQ ID NO: 35 as LCDR2, SEQ ID NO: 36 as LCDR3, SEQ ID NO: 43 as HCDR1, SEQ ID NO: 42 as HCDR2, and SEQ ID NO: 43 as HCDR3. 23. The antibody of claim 1, comprising the following CDR sequences: SEQ ID NO: 37 as LCDR1, SEQ ID NO: 38 as LCDR2, SEQ ID NO: 39 as LCDR3, SEQ ID NO: 46 as HCDR1, SEQ ID NO: 47 as HCDR2, and SEQ ID NO: 48 as HCDR3.

Details for Patent 9,758,586

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2030-12-01
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2030-12-01
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2030-12-01